Receive the latest updates from Matrix Medical in real time to understand product information.

In 2024, where opportunities and challenges coexist, Hangzhou Juzheng Medical Technology Co., Ltd. (hereinafter referred to as' Juzheng Medical ') will deeply cultivate product innovation, consolidate product quality, and strive to bring better Chinese solutions to the field of medical device intervention. The hard work of every employee, the implementation of every decision, and the advancement of every project have converged into a powerful driving force for the development of Juzheng Medical, and have also forged our extraordinary performance and profound memories over the past year. Steady progress will be made in 2024, and new momentum will be accumulated in 2025. Let's review the ups and downs of Juzheng Medical together.

 Review of past achievements and review of new articles

 Completed tens of millions of yuan Series A financing

After the angel round in 2022 and the Pre-A round in 2023, Juzheng Medical received another round of funding from well-known institutions in 2024, which fully demonstrates its strong strength and huge potential in the field of vascular intervention. The funds raised in this round of financing will continue to be used to support the clinical validation of the company's core products such as coronary artery remodeling catheters. At the same time, Juzheng Medical will further increase its research and development investment, and launch more original devices around the clinical vascular disease treatment needs with the concept of "intervention without implantation".

Innovation leads to first new certification

Project achievements

Obtained NMPA certificate for intracranial balloon dilation catheter in June 2024, and NMPA certificate for coronary artery papillary balloon dilation catheter in January 2025.

Product Progress

The company's core product pipeline, the "Natural Vessel Stent (NVS) series" coronary artery remodeling catheter and intracranial laser balloon dilation catheter (PBM product), have entered the clinical follow-up stage, and the arterial occlusion hemostatic device has been completed and replenished.

Patent recognition

The company has been awarded ISO 13485 certification by BSI. In addition, 7 new invention patents and 10 utility model patents have been applied for, laying a more solid barrier for the company's long-term development.

National project approved for honorable coronation

The enterprise has won numerous key honors and awards, adhering to the spirit of dedication and striving forward with honor.

01 National project approval and establishment

The national project "Research on Early Coronary Intervention without Implantation Treatment Technology and Management Mode" participated by Juzheng Medical has been approved for approval. This project will greatly improve the treatment effectiveness and rehabilitation prospects of early coronary heart disease patients, providing customized precision intervention and non implantation treatment strategies for early coronary heart disease patients in China. This action not only accelerated the realization process of the grand goal of "Healthy China 2030", but also marked that China is expected to achieve a historic change in reducing the incidence rate and mortality of early coronary heart disease, opening a new chapter for the health and well-being of the people.

02 Qualification certification category

 Rated as a specialized, refined, unique, and innovative small and medium-sized enterprise in Zhejiang Province

 Received recognition as a provincial-level enterprise research and development institution for the year 2024

03 Innovation Competition Category

First Prize in the 6th Medical Device Innovation and Entrepreneurship Competition of the 2024 China Biomedical Engineering Conference 

First Prize of the 7th (2024) China Medical Device Innovation and Entrepreneurship Competition

The three-year-old celebration nurtures the future

01 3rd Anniversary Celebration

Under the leadership of founder and CEO Ji Peihong, the company has flourished. We hold a special third anniversary celebration and invite all employees to share this joy and feel the power of unity and cooperation.

Founder and CEO Ji Peihong's speech in front of the stage

Group photo of all employees of Juzheng Medical

02 Establish a subsidiary company

The opening of Haohan Medical, a subsidiary of Juzheng Medical, is an important milestone in our development process and also indicates the development of the life and health industry in northern Zhejiang, which will usher in a strong new force.

03 2024 Annual Meeting Celebration

At the annual event of Juzheng Medical, Juzheng people gathered together to witness the glorious moment.

Speech and Address

At the beginning of the annual meeting, founder and CEO Ji Peihong gave a heartfelt speech, reviewing the company's glorious history in 2024 and expressing sincere gratitude to all employees for their hard work.

Professor Gu Zhongwei, Chief Scientist of Juzheng Medical, highly praised the brilliant achievements made in 2024.

Employee Commendation

At the meeting, a grand honor recognition was given to outstanding employees in 2024, and the "Outstanding Newcomer Award", "Outstanding Employee Award", and "Outstanding Contribution Award" were presented. They became role models for upright individuals through their outstanding achievements.

Lottery session

The passion of the award ceremony has not yet dissipated, and the annual lottery activity has quietly bloomed. The atmosphere on site was lively, pushing the atmosphere of the annual celebration to a climax.

 Multi dimensional cooperation promotes development together

Guided by the concept of multidimensional cooperation, we deeply collaborate with governments and medical institutions to promote comprehensive resource sharing and innovative cooperation, and jointly promote the sustainable development of the medical industry. The leaders of Yuhang District Government visited Juzheng Medical for on-site research

 Strategic cooperation has been established with the Research Institute of Transvascular Implanted Devices at Zhejiang Medical Second Hospital

Participated in the signing of the first batch of disruptive technology achievement transformation fund projects

 Conclusion

The journey is full of wind and vitality, setting sail with determination for a new journey. In 2024, Ju Zheng Medical will go through storms and hardships with unwavering dedication; In 2025, Juzheng Medical will forge ahead and embark on a new chapter. Ju Zheng Medical will face the great opportunity of sailing with the wind and sail in the tide of the times, and work hard to create brilliance!